11:54 AM EST - Clearmind Medicine Inc : Announces the filing of a patent application seeking to protect its unique combination of MEAI and SciSparc's Palmitoylethanolamide for the treatment of depression. The company filed a provisional patent application with the United States Patent and Trademark Office as part of its ongoing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat central nervous system disorders. Clearmind Medicine Inc
shares C.CMND are trading up one cent at $0.88.
